Kesimpta (ofatumumab) is generally well tolerated by most people who take it, with the most frequently reported side effects being common infections like colds and sore throats, injection-site reactions, and headaches. Clinical trials and real-world studies paint a consistent picture: while side effects are common in the broad sense, serious complications remain uncommon and the drug’s safety profile has held steady through five years of follow-up data. That said, the everyday experience of taking Kesimpta involves some practical realities that patient reviews bring into sharper focus than clinical-trial summaries alone.
What the Clinical Trials Reported
The pivotal trials that led to Kesimpta’s approval, known as ASCLEPIOS I and II, enrolled thousands of people with relapsing forms of multiple sclerosis and compared ofatumumab to teriflunomide. The most common adverse events included nasopharyngitis (essentially a cold), headache, upper respiratory tract infections, and urinary tract infections.1PubMed Central. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis These are not exotic complications; they are the kinds of things people deal with in everyday life. The difference is that on a drug designed to deplete a subset of immune cells, even a run-of-the-mill upper respiratory infection becomes something worth tracking.
Injection-related reactions occurred in about 20% of people taking Kesimpta in those trials, compared to 15% in the group receiving placebo injections. Serious infections were reported in roughly 2.5% of participants on ofatumumab versus 1.8% on the comparator drug.2PubMed. Ofatumumab versus Teriflunomide in Multiple Sclerosis The gap between the two groups was not dramatic, but it reflects the reality that B-cell-depleting therapies carry some added infection risk simply because of how they work.
Injection Reactions in Practice
In clinical trials, injection-related reactions were among the top reported side effects. But the term “injection reaction” covers a wide range, from barely-noticeable redness at the injection site to systemic symptoms like fever, chills, or body aches. Most reactions are mild and happen primarily with the first few doses. This tracks with how many anti-CD20 therapies behave: the initial doses trigger the most immune response because there are still plenty of B cells to deplete, and later doses produce far less reaction because fewer target cells remain.
A head-to-head comparison between Kesimpta and subcutaneous Ocrevus (ocrelizumab) found that people newly starting Kesimpta reported notably fewer local injection reactions after their first dose. Only about 7% experienced redness compared to 43% with subcutaneous Ocrevus, and swelling was essentially absent with Kesimpta (0%) versus 32% with Ocrevus. Pain at the injection site was reported by 32% with Kesimpta versus 46% with Ocrevus. All of the reported reactions in both groups resolved within 24 hours.3Multiple Sclerosis and Related Disorders. Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS) This is reassuring for people nervous about self-injecting: local site reactions tend to be brief and relatively mild.
One real-world study found a more nuanced story, though. After patients had been on Kesimpta for a while, the proportion reporting persistent headache after injections climbed from 10% to 26%, and limb pain rose from 5% to 26%.4PubMed Central. Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study These are the kinds of symptoms that often fly under the radar in clinical trials but show up reliably in patient reviews online. The headaches and body aches that linger for a day or two after the monthly injection are one of the more consistent complaints in real-world accounts, even among people who are otherwise happy with how the drug controls their MS.
Infection Risk Over Longer Time Frames
Because Kesimpta depletes B cells, the obvious question is whether your vulnerability to infections creeps up the longer you stay on it. Extended safety data following patients for up to three and a half years found that about 54% had at least one infection reported, which was similar to the rate seen in the original clinical trials. The most frequent infections remained familiar: colds, upper respiratory tract infections, urinary tract infections, and COVID-19 (the latter rising during the pandemic years). Importantly, the overall rate of infections did not climb with longer exposure.5PubMed Central. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
What stands out in that same dataset is what did not happen. There were zero cases of progressive multifocal leukoencephalopathy (PML), zero cases of hepatitis B reactivation, and no opportunistic infections identified. These are the serious, feared complications associated with some immune-suppressing MS therapies, and their absence in the extended data is one of the strongest reassurances in Kesimpta’s safety profile. Serious infections occurred in about 2.9% of the broader population studied, consistent with the original trial figures, and the serious infection rate did not increase over time.6PubMed Central. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Five-Year Safety Data
More recent five-year follow-up data from the ALITHIOS extension study provides the longest look at Kesimpta’s safety. Out of nearly 2,000 patients, about 90% experienced at least one adverse event over the entire observation period, which sounds high until you consider that this includes every cold, headache, and minor infection over five years. The rate at which new adverse events appeared actually declined over time compared to the initial trial period, which likely reflects both the lessening of early injection reactions and a natural plateau in infection risk.7PubMed Central. Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
COVID-19 became the most commonly reported infection in this longer dataset, affecting about 30% of participants, followed by nasopharyngitis (19%), upper respiratory infections (about 13%), and urinary tract infections (about 13%). Most infections, over 90%, resolved without the person needing to stop Kesimpta. About 7% of patients discontinued the drug due to adverse events of any kind over five years, and serious adverse events occurred in roughly 15% of the total population. No new safety signals emerged, which is the kind of finding that matters most for people considering staying on the drug long term.8PubMed Central. Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
What Happens to Immunoglobulin Levels
One concern that does not always come up in casual side-effect reviews but matters clinically is what Kesimpta does to your immunoglobulin levels over time. Immunoglobulins are the antibodies your immune system makes to fight infections. Because Kesimpta depletes the B cells responsible for producing them, there is a logical risk that antibody levels will gradually fall.
IgM antibodies seem particularly vulnerable. In one documented case, a patient on Kesimpta saw their IgM levels drop into the range classified as clinically significant hypogammaglobulinemia, while IgG levels also declined but stayed within the normal range.9PubMed Central. Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report This is worth understanding because low immunoglobulin levels can make you more susceptible to certain infections even if your day-to-day experience feels normal. Neurologists typically monitor immunoglobulin levels periodically while you are on Kesimpta, and a significant drop can influence whether you continue therapy or adjust your treatment plan.
The five-year data found that the malignancy rate remained low, at about 0.32 per 100 patient-years, consistent with earlier findings.10PubMed Central. Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis As with any immune-modulating therapy, the theoretical concern about increased cancer risk hovers in the background, but five years of data have not shown a signal that meaningfully differs from what you would expect in a general MS population. That does not close the book on the question, since cancer risks can take decades to materialize, but it is one of the more reassuring long-term data points available for any B-cell therapy in MS.
What Patient Reviews Actually Say
Clinical trial data gives you a controlled, sanitized view of side effects. Patient reviews fill in the subjective experience. The good news is that satisfaction with Kesimpta runs high. A real-world survey found that about 87% of patients rated their overall satisfaction as either “satisfied” or “extremely satisfied,” with an average score of 4.4 out of 5. People who had been on other MS therapies before switching were even happier, with over 90% reporting high satisfaction compared to 80% of those starting Kesimpta as their first treatment.11PubMed Central. Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
The autoinjector pen itself gets consistently positive marks. In a separate survey, roughly 84% of patients and nurses preferred the Kesimpta Sensoready pen over the injection devices they had been using before.12PubMed Central. Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey The top reasons people cited for their satisfaction included reasonable administration time, overall ease of use, the monthly dosing schedule, and portability. For people who had been going to infusion centers for drugs like Ocrevus or Tysabri, the ability to inject at home once a month represents a significant lifestyle improvement, and that convenience tends to color how people rate the overall treatment experience.
The less flattering reviews tend to center on a few recurring themes. Post-injection fatigue and a vague “flu-like” feeling for a day or two are common complaints, especially in online forums. The headache and limb pain findings from real-world research mirror what you hear from patients directly. Some people also report increased anxiety around injection day, particularly early on, even though the actual injection process is quick and usually painless. These are the kinds of side effects that are real and worth preparing for but rarely severe enough to drive people off the drug.
Vaccines and Blunted Immune Responses
One practical side effect of Kesimpta that gets less attention than it deserves is its impact on vaccine responses. Because the drug depletes the B cells responsible for generating antibodies, your ability to mount a robust antibody response to vaccines can be reduced. Research has shown that while some disease-modifying therapies in MS reduce humoral (antibody-based) vaccine responses, they may still provide some protection through adequate T-cell responses.13PubMed Central. Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis
In practice, this means you should ideally get any necessary vaccinations, especially live vaccines, before starting Kesimpta. Once you are on it, inactivated vaccines like the flu shot or COVID boosters are still recommended, but you may not generate as strong an antibody response as someone with a full complement of B cells. This does not mean vaccines are pointless on Kesimpta. T-cell immunity, which is largely preserved, still provides meaningful protection. But it is something to discuss with your neurologist, particularly around timing of seasonal vaccines or travel-related immunizations.
Pregnancy Considerations
Kesimpta has not been studied in pregnant people through controlled trials, so the available information comes mainly from animal research. In primate studies, ofatumumab crossed the placenta and was detectable in infant animals for weeks to months after birth, depending on the dose. In the lower-dose group, the drug was measurable in some infants up to about two months after birth, while in the higher-dose group it was detectable in all infants for up to three months.14Reproductive Toxicology. Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys This raises theoretical concerns about immune effects on a developing baby, since the drug would be depleting B cells in the infant during a critical period of immune development.
The practical guidance from neurologists is generally to stop Kesimpta before a planned pregnancy, allowing time for B cells to recover. Kesimpta’s shorter half-life compared to intravenous anti-CD20 therapies means B-cell repopulation begins sooner after discontinuation, which is a relative advantage for family planning. But the tradeoff is real: stopping any effective MS therapy carries a risk of disease reactivation, which means the timing conversation needs to be individualized rather than governed by a one-size-fits-all rule. Monoclonal antibodies used in MS carry potential risks including infections and, in rare cases, secondary autoimmune conditions or malignancies, all of which factor into the risk-benefit equation during reproductive years.15PubMed Central. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
What Happens When You Stop Kesimpta
Patient reviews sometimes touch on the experience of pausing or stopping Kesimpta, and this is an area where the drug’s pharmacology makes the situation a bit different from other anti-CD20 therapies. Kesimpta has a shorter elimination half-life than intravenous options like ocrelizumab, meaning B cells start to repopulate sooner after you stop injecting. That sounds like a safety feature, and it is in some respects, but it also means that gaps in treatment can lead to disease activity bouncing back more quickly.
A case report documented increased MS disease activity following just a four-month interruption of Kesimpta therapy, with the relapse timing consistent with the drug’s known pharmacokinetics and the expected window for B-cell repopulation.16International Journal of Multiple Sclerosis Care. Ofatumumab Interruption Results in Disease Reactivation: A Case Report This is relevant to the side-effect conversation because some people stop or pause their treatment specifically because of side effects, and the decision to do so carries its own risks. If you are considering a break from Kesimpta due to persistent headaches, fatigue, or other bothersome symptoms, the conversation with your neurologist should weigh those side effects against the possibility that your MS could flare within a few months of stopping.
The overall picture from both clinical trials and real-world reviews is that Kesimpta’s side-effect profile sits in a manageable range for most people. The most disruptive everyday complaints, post-injection headaches, fatigue, and the occasional cold, are real but tolerable for the majority. The more serious risks, like significant infections or declining immunoglobulin levels, require monitoring but have not shown escalating patterns over five years of observation. For many patients, the convenience of self-injection at home and the strong efficacy against relapses outweigh the monthly day or two of feeling under the weather, which is why satisfaction ratings remain as high as they are even when people freely report their side effects.